FDA Update: Topical Plaque Psoriasis Treatment Approved; Dupilumab Will Receive FDA Priority Review
Rituximab Receives Label Update for ANCA-Associated Vasculitis
FDA Approves Subcutaneous Tocilizumab for Ages 2–17
Plaque Psoriasis Treatments: BMS-986165 Promising & Adalimumab Biosimilar Demonstrates Equivalence
Revised Application Expected for IV Meloxicam; Plus EU Approves Tildrakizumab
More Evidence TNF Inhibitors Raise Risk of Peripheral Neuropathy
TNFi Exposure in Utero
Placebos: Their Underappreciated Impact in Pharmaceutical Trials
Piclidenoson in Trials for Psoriasis & RA; Plus Duzallo Approved in Europe
- 1
- 2
- 3
- …
- 15
- Next Page »